Skip to content
value.today

Arch Therapeutics, Inc.

Formerly ALMAH, INC.

Total raised
$17 M
4 rounds on record
Latest round
$4 M
Jul 2022
First round on record
Feb 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Arch Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2022$4 MNo. 4$2 to $10 million

Arch Therapeutics, Inc.: Raise no. 4, Jul 2022

Investors in this round

16 investors had bought by the notice of Jul 19, 2022: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$240,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Daniel M. Yrigoyen · Executive Officer
  • Michael S. Abrams · Executive Officer
  • Terrence W. Norchi · Executive Officer, Director
  • Guy W. Fish · Director
  • Laurence W. Hicks · Director
  • Punit W. Dhillon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLP (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3. Additionally, warrants were issued to the placement agent at an exercise price of $0.0503 per share.”

Signed by Michael S. Abrams, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 19, 2022. Read the notice at the SEC.

equity, optionsSEC
Feb 2021$7 MNo. 3$2 to $10 million

Arch Therapeutics, Inc.: Raise no. 3, Feb 2021

Investors in this round

9 investors had bought by the notice of Feb 25, 2021: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $8 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$492,750
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Richard E. Davis · Executive Officer
  • Terrence W. Norchi · Executive Officer, Director
  • James R. Sulat · Director
  • Punit W. Dhillon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. (CRD 375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Excludes value of warrants to purchase up to 3,234,375 shares at an exercise price of $0.20 per share”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.”

Signed by Terrence Norchi, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 25, 2021. Read the notice at the SEC.

equity, optionsSEC
May 2016$3 MNo. 2$2 to $10 million

Arch Therapeutics, Inc.: Raise no. 2, May 2016

Investors in this round

18 investors had bought by the notice of Jun 2, 2016: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$170,960
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Richard E. Davis · Executive Officer
  • Terrence W. Norchi · Executive Officer, Director
  • Avtar W. Dhillon · Director
  • James R. Sulat · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MAXIM GROUP LLC (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.”

Signed by Terrence Norchi, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 2, 2016. Read the notice at the SEC.

equity, optionsSEC
Feb 2014$3 MNo. 1$2 to $10 million

Arch Therapeutics, Inc.: Raise no. 1, Feb 2014

Investors in this round

9 investors had bought by the notice of Feb 7, 2014: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Alan Barber · Executive Officer
  • Norchi Terrence · Executive Officer, Director
  • William Cotter · Executive Officer
  • Arthur Rosenthal · Director
  • Avtar Dhillon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Terrence Norchi, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 7, 2014. Read the notice at the SEC.

equity, optionsSEC
Jun 2013$7 MIssued in a merger or acquisition$2 to $10 million

Arch Therapeutics, Inc.: Private sale, Jun 2013

Investors in this round

58 investors had bought by the notice of Jul 8, 2013: 52 accredited, 6 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Alan W Barber · Executive Officer
  • Terrence W Norchi · Executive Officer, Director
  • Arthur W Rosenthal · Director
  • Avtar W Dhillon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Calculated based on a per share price of $0.50, which is the price paid for the Issuer's common stock by an investor in a recent separate private placement and was used due to the limited trading market for the Issuer's common stock.”
  • On a merger: “Shares of common stock issued in exchange for the cancellation of equity or rights to acquire equity of Arch Biosurgery, Inc. upon the closing of a reverse merger with such entity.”

Signed by Terrence W. Norchi, President, chief executive officer. Source: SEC Form D, newest notice filed Jul 8, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Arch Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2022).

    SEC Form D · Jul 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2022

That is all the official record says: Arch Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Arch Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 18 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arch Therapeutics, Inc.
NameRoleNamed in
Daniel M. YrigoyenExecutive officerJul 2022
Michael S. AbramsExecutive officerJul 2022
Terrence W. NorchiExecutive officerJul 2022
Richard E. DavisExecutive officerFeb 2021
Alan BarberExecutive officerFeb 2014
Norchi TerrenceExecutive officerFeb 2014
William CotterExecutive officerFeb 2014
Alan W BarberExecutive officerJul 2013
Terrence W NorchiExecutive officerJul 2013
Guy W. FishDirectorJul 2022
Laurence W. HicksDirectorJul 2022
Punit W. DhillonDirectorJul 2022
Terrence W. NorchiDirectorJul 2022
James R. SulatDirectorFeb 2021
Avtar W. DhillonDirectorJun 2016
Arthur RosenthalDirectorFeb 2014
Avtar DhillonDirectorFeb 2014
Norchi TerrenceDirectorFeb 2014
Arthur W RosenthalDirectorJul 2013
Avtar W DhillonDirectorJul 2013
Terrence W NorchiDirectorJul 2013